IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE

摘要

It was discovered that using an antigen-binding molecule having a cancer-specific antigen-binding domain and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain makes it possible to activate immune cells by actualizing agonist activity against factors belonging to the TNF superfamily or TNF receptor superfamily only in the presence of cancer-specific antigen-expressing cells, and to avoid hepatotoxicity and other such side effects while maintaining anti-tumor activity. It was also discovered that using an antigen-binding molecule having a cancer-specific antigen-binding domain and a T-cell-receptor-complex-binding domain in combination with this antigen-binding molecule makes it possible to improve the anti-tumor activity while avoiding side effects.